TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05025501

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family based Executive Function Training
Description: Training the executive funtions of shcoolage ADHD children through tasks and games repeatly but with fun. Giving the parental training and support for the parenting role parents strategies to help the shcoolage ADHD childred coping the symptoms and develop EF in the reallife and improve parent-child relationship.
Study: NCT04529265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene Blue
Description: Intraoperative infusion of 2mg/kg MB after induction of anesthesia and 1mg/kg MB at the end of surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Equal volume of normal saline after induction of anesthesia and at the end of surgery
Study: NCT06230068

Intervention type: OTHER
Group type: OTHER
Intervention: Expressive writing
Description: See description under arm/group description.
Study: NCT04891796

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT04581200

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lift
Description: The intervention is a mobile app-based mindfulness training program designed to be used over a 1-month period.
Study: NCT06304662

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga intervention
Description: Over 12 weeks, students will attend 50-minute yoga sessions twice a week. Sessions start with 10 minutes of mindful breathing and gentle warm-up movements, followed by 30 minutes of tailored yoga postures for relaxation and stretching. Students progress from basic to advanced postures, with adaptations for individual needs. Each session ends with a guided meditation for inner calm. A 10-minute cool-down encourages deep relaxation. Emphasis is on stress reduction, flexibility, and mindfulness, tailored to university life challenges. Continuous assessment ensures sessions meet students' evolving needs and optimize yoga's benefits in the university setting.
Study: NCT05244811

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combined Oral Contraceptive
Description: effect of cocs in treatment of ovarian cysts

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Combined Oral Contraceptive
Description: effect of cocs in treatment of ovarian cysts

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combined Oral Contraceptive
Description: effect of cocs in treatment of ovarian cysts

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progestin
Description: effect of progestin in treatment of ovarian cystn

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Progestin
Description: effect of progestin in treatment of ovarian cystn

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progestin
Description: effect of progestin in treatment of ovarian cystn
Study: NCT06444022

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human amniotic epithelial stem cells（hAESCs）
Description: Human Amniotic Epithelial Cells Prevent Acute Graft-versus-host Disease After Hematopoietic Stem Cell Transplantation (hAECs-GVHD)
Study: NCT04973332

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intracranial thrombectomy stent
Description: Intracranial thrombectomy stents for ischemic stroke patients within 24 hours of symptom onset
Study: NCT06480851

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ecoguided Percutaneous Neuromodulation
Description: Ecoguided Percutaneous Neuromodulation over the posterior branch of the cervical multifidus, for 10 minutes, with a frequency of 10 HZ.
Study: NCT06444022

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo (cell preservation solution)
Description: Same dose placebo (cell preservation solution) injections as control group
Study: NCT06344234

Intervention type: DIAGNOSTIC_TEST
Intervention: End-inspiratory Maneuvers
Description: Airway pressure, flow, and esophageal pressure will be continuously recorded in all patients using a dedicated pneumotachograph and pressure transducer: all signals will be acquired and stored. Once a stable ventilation pattern is observed NIV will be administered by setting ventilator in invasive-pressure support ventilation. PEEP and PS-level will by kept constant while expiratory trigger will be adjusted to optimize patient-ventilatory synchrony. Immediately after, sudden end-inspiratory and end-expiratory occlusion maneuvers will be performed to measure plateau pressure and end-expiratory airway occlusion pressure (ΔPocc), respectively. Invasive PSV will be used only to perform the occlusion maneuvers, subsequently, PSV will be delivered in non-invasive PSV mode. Patient's blood-gas parameters and vital signs will be collected, including discomfort assessment. During the occlusion maneuvers, diaphragm ultrasound will be performed, and images will be recorded.
Study: NCT05425511

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: sophrology / neurolinguistic programming intervention
Description: 2 sessions will be offered per week at 2 different time and will last 1 hour. They can take place in a seated or standing position, without physical contact. The sessions will consist of breathing exercises, visualization, dynamic relaxation and concentration exercises. The program is standardized:~1. Dialogue between the sophrologist and the participants. It is possible to specify the objective(s) of the session. The sophrologist can ask more specific questions to adapt the session.~2. Presentation of the conduct of the session (possible variations) and instructions promoting autonomy~3. Guided by the sophrologist, the goal is to help free yourself from tensions, to play down a situation that worries and finally to realize that we can deal with. Exercises are adapted to the difficulties encountered by the participants.~4. Time for free expression after the practice to promote the integration of the technique while giving elements to the sophrologist to guide the future sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sophrology / neurolinguistic programming intervention
Description: 2 sessions will be offered per week at 2 different time and will last 1 hour. They can take place in a seated or standing position, without physical contact. The sessions will consist of breathing exercises, visualization, dynamic relaxation and concentration exercises. The program is standardized:~1. Dialogue between the sophrologist and the participants. It is possible to specify the objective(s) of the session. The sophrologist can ask more specific questions to adapt the session.~2. Presentation of the conduct of the session (possible variations) and instructions promoting autonomy~3. Guided by the sophrologist, the goal is to help free yourself from tensions, to play down a situation that worries and finally to realize that we can deal with. Exercises are adapted to the difficulties encountered by the participants.~4. Time for free expression after the practice to promote the integration of the technique while giving elements to the sophrologist to guide the future sessions.
Study: NCT05275491

Intervention type: DIAGNOSTIC_TEST
Intervention: Calcium
Description: Free calcium serum levels

Intervention type: DIAGNOSTIC_TEST
Intervention: Calcium
Description: Free calcium serum levels

Intervention type: DIAGNOSTIC_TEST
Intervention: Calcium
Description: Free calcium serum levels

Intervention type: DIAGNOSTIC_TEST
Intervention: Fibroblast growth factor 23
Description: Serum level

Intervention type: DIAGNOSTIC_TEST
Intervention: Fibroblast growth factor 23
Description: Serum level

Intervention type: DIAGNOSTIC_TEST
Intervention: Fibroblast growth factor 23
Description: Serum level
Study: NCT06335693

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: The patients after radical prostatectomy with high-risk pathological factors will receive adjuvant hypofractionated radiation therapy in 15 fractions.
Study: NCT05275491

Intervention type: DIAGNOSTIC_TEST
Intervention: Sclerostin
Description: Serum level

Intervention type: DIAGNOSTIC_TEST
Intervention: Sclerostin
Description: Serum level

Intervention type: DIAGNOSTIC_TEST
Intervention: Sclerostin
Description: Serum level

Intervention type: DIAGNOSTIC_TEST
Intervention: parathyroid hormone
Description: serum level
Study: NCT06480851

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ecoguided Percutaneous Neuromodulation
Description: Ecoguided Percutaneous Neuromodulation over the posterior branch of the cervical multifidus, for 10 minutes, with a frequency of 10 HZ.
Study: NCT05275491

Intervention type: DIAGNOSTIC_TEST
Intervention: parathyroid hormone
Description: serum level

Intervention type: DIAGNOSTIC_TEST
Intervention: parathyroid hormone
Description: serum level
Study: NCT04764292

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced mammography
Description: supplemental breast cancer screening with contrast-enhanced mammography

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iodinated Contrast Media (ICM)
Description: supplemental breast cancer screening with contrast-enhanced mammography
Study: NCT06363058

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ES Cycling Training
Description: Implementing Electrical Stimulation (ES) Cycling combined with priming strategies to enhance motor learning tasks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ES Cycling Training
Description: Implementing Electrical Stimulation (ES) Cycling combined with priming strategies to enhance motor learning tasks
Study: NCT06419218

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School meal messages
Description: Messages focused on the benefits of children consuming school lunch and breakfast, using text and images developed based on parent interviews. Participants will view a total of 10 messages.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control (neutral) messages
Description: Control messages approximately matched to the intervention messages on length and design, but discussing a neutral topic unrelated to school meals (reading). Participants will view a total of 10 messages.
Study: NCT05030259

Intervention type: PROCEDURE
Intervention: fasciotomy
Description: To perform fasciotomy
Study: NCT06188455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib Capsules
Description: Oral administration of 100 mg, 2 capsules/time (50 mg/capsule), twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate Tablets
Description: Oral administration of 250 mg each time, 1 tablet/time (250 mg/tablet)
Study: NCT06260111

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation
Description: Photobiomodulation will be used in sessions of approximately 5 to 10 minutes each. An InGaIP diode laser will be used with the following parameters: wavelength of 660 nm, output power of 40 mW, and an energy density of 4 J/cm2 measured at the end of the fiber optic with 0.04 cm2 of section area. The laser will be applied at 10 points in each oral region, with an exposure time of 4 s per point, using 0.16 J of energy per point.~The protocol was based on previous studies.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Usual care for oral mucositis includes education, cryotherapy, and mouth hygiene.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Usual care for oral mucositis includes education, cryotherapy, and mouth hygiene.
Study: NCT06323746

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Denneroll cervical traction orthodontic
Description: The duration of each session will start at approximately three minutes and increase by one minute per session until reaching the goal of 20 minutes per session. The intervention will be repeated three times per week for 10 weeks in the supervised setting.

Intervention type: DEVICE
Group type: OTHER
Intervention: Denneroll cervical traction orthodontic
Description: The duration of each session will start at approximately three minutes and increase by one minute per session until reaching the goal of 20 minutes per session. The intervention will be repeated three times per week for 10 weeks in the supervised setting.
Study: NCT05147519

Intervention type: BEHAVIORAL
Intervention: Novel interventions to achieve HIV remission
Description: To establish a group of well-characterized people living with HIV who initiated ART during acute or early HIV transmission that can serve as a source population for future studies, including those designed to test novel interventions to achieve HIV remission.

Intervention type: BEHAVIORAL
Intervention: Novel interventions to achieve HIV remission
Description: To establish a group of well-characterized people living with HIV who initiated ART during acute or early HIV transmission that can serve as a source population for future studies, including those designed to test novel interventions to achieve HIV remission.

Intervention type: BEHAVIORAL
Intervention: Novel interventions to achieve HIV remission
Description: To establish a group of well-characterized people living with HIV who initiated ART during acute or early HIV transmission that can serve as a source population for future studies, including those designed to test novel interventions to achieve HIV remission.
Study: NCT04772053

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor biopsy
Description: Archived or fresh tumor biopsy samples will be collected.
Study: NCT05168813

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Moderna mRNA-1273
Description: COVID-19 vaccine (mRNA-1273) developed by Moderna, Inc. is a lipid nanoparticle (LNP) dispersion of a messenger ribonucleic acid (mRNA) encoding the prefusion stabilized S protein of SARS-CoV-2 formulated in LNPs composed of 4 lipids (1 proprietary and 3 commercially available).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Moderna mRNA-1273
Description: COVID-19 vaccine (mRNA-1273) developed by Moderna, Inc. is a lipid nanoparticle (LNP) dispersion of a messenger ribonucleic acid (mRNA) encoding the prefusion stabilized S protein of SARS-CoV-2 formulated in LNPs composed of 4 lipids (1 proprietary and 3 commercially available).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Moderna mRNA-1273
Description: COVID-19 vaccine (mRNA-1273) developed by Moderna, Inc. is a lipid nanoparticle (LNP) dispersion of a messenger ribonucleic acid (mRNA) encoding the prefusion stabilized S protein of SARS-CoV-2 formulated in LNPs composed of 4 lipids (1 proprietary and 3 commercially available).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Moderna mRNA-1273
Description: COVID-19 vaccine (mRNA-1273) developed by Moderna, Inc. is a lipid nanoparticle (LNP) dispersion of a messenger ribonucleic acid (mRNA) encoding the prefusion stabilized S protein of SARS-CoV-2 formulated in LNPs composed of 4 lipids (1 proprietary and 3 commercially available).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine 3 Dose
Description: COVID-19 mRNA vaccine in 100 mcg dose given as IM injection into the deltoid muscle on Day 1, Day 29, and Day 169.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine 3 Dose
Description: COVID-19 mRNA vaccine in 100 mcg dose given as IM injection into the deltoid muscle on Day 1, Day 29, and Day 169.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine 2 Dose
Description: COVID-19 mRNA vaccine is to be administered as IM injection into the deltoid muscle on Day 1 and Day 169.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine 2 Dose
Description: COVID-19 mRNA vaccine is to be administered as IM injection into the deltoid muscle on Day 1 and Day 169.
Study: NCT05960370

Intervention type: OTHER
Intervention: Observational non intervention study
Description: An additional control scan will be performed vaginally the day of the embryo transfer. Rest of follow up and treatment will be executed as usually.

Intervention type: OTHER
Intervention: Observational non intervention study
Description: An additional control scan will be performed vaginally the day of the embryo transfer. Rest of follow up and treatment will be executed as usually.
Study: NCT05141903

Intervention type: DIETARY_SUPPLEMENT
Intervention: Dietary supplement, probiotic, antibiotic conditioning -all groups
Description: Dietary supplement, probiotic, antibiotic conditioning -all groups

Intervention type: DIETARY_SUPPLEMENT
Intervention: Dietary supplement, probiotic, antibiotic conditioning -all groups
Description: Dietary supplement, probiotic, antibiotic conditioning -all groups

Intervention type: DIETARY_SUPPLEMENT
Intervention: Dietary supplement, probiotic, antibiotic conditioning -all groups
Description: Dietary supplement, probiotic, antibiotic conditioning -all groups

Intervention type: DIETARY_SUPPLEMENT
Intervention: Dietary supplement, probiotic, antibiotic conditioning -all groups
Description: Dietary supplement, probiotic, antibiotic conditioning -all groups

Intervention type: DIETARY_SUPPLEMENT
Intervention: Dietary supplement, probiotic, antibiotic conditioning -all groups
Description: Dietary supplement, probiotic, antibiotic conditioning -all groups
Study: NCT04929808

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrating emollient for acute radiodermatitis
Description: The emollient has a calming effect, and hydrating and anti-oxidative properties.~An absorbable wound dressing will be applied on painful and moist wounds. In case of severe itch, a systemic antihistaminic agent can be prescribed by the radiotherapist.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard institutional skin care
Description: The control patients will receive the institutional standard skin care, which includes the application of Flamigel® (Flen Pharma, Kontich, BELGIUM). In addition, Mepilex® (Mölnlycke Health Care, Berchem, Belgium), an absorbable wound dressing will be applied on painful and moist wounds. In case of severe itch, a systemic antihistaminic agent can be prescribed by the radiotherapist.
Study: NCT05715359

Intervention type: PROCEDURE
Intervention: Reconstruction
Description: Standardized template for reconstruction of continious defects of the jaws.
Study: NCT05295914

Intervention type: DIAGNOSTIC_TEST
Intervention: TREAT-B score
Description: TREAT-B score: ALT(alanine transferase), HBeAg REACH-B score: sex, ALT, HBV viral load, age WHO-simplified score: ALT, cirrhosis
Study: NCT05958160

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Atkins diet
Description: The modified Atkins diet is a less restrictive version of the ketogenic diet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topiramate
Description: Topiramate is an anti-seizure medication
Study: NCT04821271

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Arm 1 and 2 Control Intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Arm 1 and 2 Control Intervention

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-161 (50 - 100 mg)
Description: Arm 1 and 2 Experimental Intervention

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-161 (50 - 100 mg)
Description: Arm 1 and 2 Experimental Intervention
Study: NCT04011579

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MSFIT
Description: MSFIT, by using the Microsoft Kinect Motion Controller Xbox to deliver adapted physical activity, offers the possibility to transform the Pilates exercises into a virtual reality game. Each exercise is implemented with different levels of difficulty in order to allow the adaptation to the capacities of the user.
Study: NCT05272670

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A digital foot self-management program
Description: A 4-week digital foot self-management program based on Bandura's Self-Efficacy model. The proposed functions include checking conditions of foot, cleaning, cutting or removing corns and calluses, trimming, clipping nails, foot exercise, dietary related to foot care, foot care logs, etc. Which was developed for older adults with diabetic foot self-management by the study team. Week 1 one-hour face-to-face training session after participant recruitment and allocation. The outline session is 30 min to introduce key topics and function in the app platform, 15 min to install the app and to demonstrate the use of the app, 15min to discuss and practice. Week 2 to week 4 following phone call once per week at the end of week and LINE messages 3 times per week.by research nurse, who will encourage and monitor participant's compliance with the program at home by using the digital platform. Participants are informed that technical phone support is available during the trial.
Study: NCT06153602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine Hydrochloride 10 MG/ML
Description: Nalbuphine(10mg/ml) 0.8 mg intrathecal

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0.9 % in 5 ML Injection
Description: 0.9% Sodium Chloride 0.08 ml intrathecal

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine Hydrochloride, Spinal
Description: 0.5% Hyperbaric or Isobaric Spinal Bupivacaine 1-4 ml intrathecal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride, Spinal
Description: 0.5% Hyperbaric or Isobaric Spinal Bupivacaine 1-4 ml intrathecal

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nalbuphine Hcl 10Mg/Ml Inj
Description: 4 mg IV prn for postoperative pain score\>=4 q 6 h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine Hcl 10Mg/Ml Inj
Description: 4 mg IV prn for postoperative pain score\>=4 q 6 h

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetaminophen 500Mg Tab
Description: 1 tab oral prn for postoperative pain score 1-3 q 6 h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen 500Mg Tab
Description: 1 tab oral prn for postoperative pain score 1-3 q 6 h

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ondansetron 8mg
Description: 8 mg IV prn for nausea or vomiting q 8 h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron 8mg
Description: 8 mg IV prn for nausea or vomiting q 8 h
Study: NCT05127798

Intervention type: OTHER
Intervention: Evaluation of first line treatment with intensive treatment outcome in adult patients with AML.
Description: Evaluation of first line treatment with intensive treatment outcome (or event free survival and overall survival and toxicity) in adult patients between 18 and 70 years old with AML.
Study: NCT05221346

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plant food supplement
Description: Food supplements are consumed during 3 weeks by hypercholesterolemic volunteers

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Food supplements are consumed during 3 weeks by hypercholesterolemic volunteers